Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Sep;10(9):941-5.
doi: 10.1038/embor.2009.193.

The case for open-access chemical biology. A strategy for pre-competitive medicinal chemistry to promote drug discovery

Johan Weigelt  1
Affiliations

The case for open-access chemical biology. A strategy for pre-competitive medicinal chemistry to promote drug discovery

Johan Weigelt. EMBO Rep. 2009 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The author declares no conflict of interest beyond his affiliation to the Structural Genomics Consortium as noted below.

Figures

Figure 1
Figure 1
Three models of the interaction between pharmaceutical companies and academia. (A) The traditional model comprises a closed collaboration between a company and an academic researcher. (B) The closed consortium model in which several parties contribute to a joint project. Results and/or intellectual property rights are normally retained by consortium members. (C) The open consortium model in the form of a public–private partnership. A joint project, governed by its funders, is carried out at a host institution or as a separate legal entity. Results are made freely available to allow research in the public domain.
Figure 2
Figure 2
Model of the open-access chemical biology consortium. The public–private partnership (PPP) is mandated to create chemical probes that target proteins involved in epigenetic signalling. Results—tools and data—are shared freely to facilitate further exploration and new discoveries. The increased knowledge will allow commercial projects at a later stage with an increased chance of success. The model can also be viewed as a general scheme for pre-competitive public–private collaboration. The Structural Genomics Consortium was originally created as a structural genomics PPP following the same principles.
None
See this image and copyright information in PMC

References

    1. Avvakumov GV, Walker JR, Xue S, Li YJ, Duan SL, Bronner C, Arrowsmith CH, Dhe-Paganon S (2008) Structural basis for recognition of hemi-methylated DNA by the SRA domain of human UHRF1. Nature 455: 822–825 - PubMed
    1. Barr AJ, Ugochukwu E, Lee WH, King ONF, Filippakopoulos P, Alfano I, Savitsky P, Burgess-Brown NA, Muller S, Knapp S (2009) Large-scale structural analysis of the classical human protein tyrosine phosphatome. Cell 136: 352–363 - PMC - PubMed
    1. Baumli S, Lolli G, Lowe ED, Troiani S, Rusconi L, Bullock AN, Debreczeni JE, Knapp S, Johnson LN (2008) The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation. EMBO J 27: 1907–1918 - PMC - PubMed
    1. Betz UA (2005) How many genomics targets can a portfolio afford? Drug Discov Today 10: 1057–1063 - PubMed
    1. Booth B, Zemmel R (2004) Prospects for productivity. Nat Rev Drug Discov 3: 451–456 - PubMed

Publication types

MeSH terms